SLCO1B1 variants and statin-induced myopathy--a genomewide study.

By E. Link, S. Parish, J. Armitage, L. Bowman, S. Heath, F. Matsuda, Ivo G. Gut, M. Lathrop, R. Collins. New England Journal of Medicine, 2008

2,015 citations recorded by the source corpus.

Subfields: Cell Biology, Oncology, Surgery

View Paper: https://www.semanticscholar.org/paper/3a3f029c7984ec4d0dcc692298a77f53356f1753

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Cell Biology

1. Christoph Borner

In Oncology

1. Christoph Borner
2. M. Niemi
3. A. Kalliokoski

In Surgery

1. A. Ramachandran
2. H. Jaeschke
3. R. Bilous
4. J. Tobert

Citations in the corpus

• Impact of OATP transporters on pharmacokinetics (2009, background): “The most convincing data on the clinical significance of the SLCO1B1 polymorphism comes from a recent genome-wide association study investigating simvastatin-induced myopathy (Link et al., 2008).”
• Quality Control Procedures for Genome Wide Association Studies (2011, background): “More recently, GWAS are being conducted in cohorts that are clinic-based (Link et al., 2008; Daly et al., 2009; Thompson et al., 2009; Barber et al., 2010).”
• Recent advances in 2D and 3D in vitro systems using primary hepatocytes, alternative hepatocyte sources and non-parenchymal liver cells and their use in investigating mechanisms of hepatotoxicity, cell signaling and ADME (2013, positive): “Notably, the genetic variant OATP1B1*5 has been shown to be significantly associated with a higher risk for statin-induced myopathy (Link et al. 2008).”